INBP (Integrated Biopharma) Tariff Resilience Score: 4/10 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBP Integrated Biopharma Inc INBP
36 GF Score
Price $0.16
GF Value $0.26
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Integrated Biopharma Tariff Resilience Score?

Integrated Biopharma INBP 36 Tariff Resilience Score is 4 as of Jul. 31, 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 2,045 Consumer Packaged Goods companies, Integrated Biopharma ranks better than 90.81% on this metric.

Integrated Biopharma has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Integrated Biopharma has Integrated Biopharma is exposed to tariffs due to its reliance on imported raw materials for nutraceuticals. It faces moderate risks from trade tensions, but has some mitigation strategies through alternative suppliers. Historical impacts have been notable.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Integrated Biopharma might have Average Resilient.

Integrated Biopharma  (OTCPK:INBP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Integrated Biopharma Tariff Resilience Score Related Terms

INBP vs HCWC, PAVS, BABB: Tariff Resilience Score Comparison

For the Packaged Foods subindustry, Integrated Biopharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Biopharma Tariff Resilience Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Tariff Resilience Score falls into.


INBP
36GF Score
Integrated Biopharma Inc INBP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
Integrated Biopharma (INBP) has a Tariff Resilience Score of 4 as of Jul. 31, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Integrated Biopharma ranks #188 out of 2045 companies in the Consumer Packaged Goods industry, placing it in the top 9.2%.
Is Integrated Biopharma's Tariff Resilience Score too high?
Integrated Biopharma's current Tariff Resilience Score is 4. Based on the distribution chart, Integrated Biopharma ranks #188 out of 2045 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's Tariff Resilience Score compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #188 out of 2045 companies for Tariff Resilience Score. This places Integrated Biopharma in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Consumer Packaged Goods company?
A good Tariff Resilience Score depends on the Consumer Packaged Goods industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Integrated Biopharma's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current Tariff Resilience Score is 4. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current Tariff Resilience Score is 4 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Biopharma (INBP) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued. The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26. GuruFocus considers Integrated Biopharma to be Possible Value Trap.

Key valuation signals for INBP:

  • Tariff Resilience Score: 4
  • GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integrated Biopharma Business Description

Address 225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score

Get the complete analysis for INBP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price
$0.26
GF Value